PMID- 30910714
OWN - NLM
STAT- MEDLINE
DCOM- 20200128
LR  - 20200128
IS  - 1879-0542 (Electronic)
IS  - 0165-2478 (Linking)
VI  - 209
DP  - 2019 May
TI  - TNFR2 but not TNFR1 is the main TNFR expressed by B and T lymphocytes in breast 
      cancer draining lymph nodes.
PG  - 36-44
LID - S0165-2478(18)30600-X [pii]
LID - 10.1016/j.imlet.2019.03.013 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) is a key cytokine in inflammation and a driving 
      force for leukocyte migration and recruitment. However, it may exert contrasting 
      effects on the immune responses depend on its differential binding to its 
      receptors (TNFR1 or TNFR2). The expression of TNF receptors by lymphocytes in the 
      tumor draining lymph nodes (TDLNs) has not been thoroughly investigated. Herein, 
      the expression of TNFRs on lymphocytes in the breast TDLNs was assessed. 40 
      axillary LN samples were obtained from breast cancer patients. Mononuclear cells 
      were isolated using Ficoll-Hypaque gradient centrifugation and stained with 
      anti-CD3, CD4, CD8, CD19, TNFR1 and TNFR2 and subjected to flow cytometry. 
      Results showed that TNFR2 was detected on unstimulated B or T cells in the breast 
      TDLNs while TNFR1 was nearly absent on these cells. Short or long term activation 
      did not increase the expression of TNFR1. The percentage of TNFR2(+) cells was 
      significantly higher in CD4(+) compared to CD19(+) or CD8(+) cells. No 
      significant association was observed between the percentage of TNFR2 expressing T 
      cells and prognostic indicators. However, the percentage of TNFR2(+) B cells in 
      the metastatic LNs had negative associations with tumor grade and the number of 
      involved LNs (P = 0.009 and P = 0.04, respectively). Collectively, TNFR2 was the 
      main TNFR expressed by unstimulated B or T lymphocytes in the breast TDLNs and 
      the frequency of TNFR2(+) B cells was connected to good prognosticators. The 
      effects of TNFR2 expression by lymphocytes of breast TDLNs on their functions 
      requires more functional studies.
CI  - Copyright (c) 2019 European Federation of Immunological Societies. Published by 
      Elsevier B.V. All rights reserved.
FAU - Ghods, Atri
AU  - Ghods A
AD  - Department of Immunology, School of Medicine, Shiraz University of Medical 
      Sciences, Shiraz, Iran; Shiraz Institute for Cancer Research, School of Medicine, 
      Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Ghaderi, Abbas
AU  - Ghaderi A
AD  - Department of Immunology, School of Medicine, Shiraz University of Medical 
      Sciences, Shiraz, Iran; Shiraz Institute for Cancer Research, School of Medicine, 
      Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Shariat, Mahmoud
AU  - Shariat M
AD  - Department of Pathology, Shiraz Central Hospital, Shiraz, Iran.
FAU - Talei, Abdol-Rasoul
AU  - Talei AR
AD  - Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, 
      Iran.
FAU - Mehdipour, Fereshteh
AU  - Mehdipour F
AD  - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of 
      Medical Sciences, Shiraz, Iran. Electronic address: mehdipourf@sums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190322
PL  - Netherlands
TA  - Immunol Lett
JT  - Immunology letters
JID - 7910006
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type II)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Animals
MH  - B-Lymphocytes/immunology/*metabolism
MH  - Breast Neoplasms/*genetics/*metabolism/pathology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lymph Nodes/immunology
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor, Type I/*genetics/metabolism
MH  - Receptors, Tumor Necrosis Factor, Type II/*genetics/metabolism
MH  - T-Lymphocytes/immunology/*metabolism
MH  - Tumor Burden
OTO - NOTNLM
OT  - Breast cancer
OT  - Lymphocytes
OT  - TNF receptors
OT  - Tumor draining lymph nodes
EDAT- 2019/03/27 06:00
MHDA- 2020/01/29 06:00
CRDT- 2019/03/27 06:00
PHST- 2018/12/24 00:00 [received]
PHST- 2019/03/06 00:00 [revised]
PHST- 2019/03/20 00:00 [accepted]
PHST- 2019/03/27 06:00 [pubmed]
PHST- 2020/01/29 06:00 [medline]
PHST- 2019/03/27 06:00 [entrez]
AID - S0165-2478(18)30600-X [pii]
AID - 10.1016/j.imlet.2019.03.013 [doi]
PST - ppublish
SO  - Immunol Lett. 2019 May;209:36-44. doi: 10.1016/j.imlet.2019.03.013. Epub 2019 Mar 
      22.